KYRIX Trademark

Trademark Overview


On Sunday, May 15, 2022, a trademark application was filed for KYRIX with the United States Patent and Trademark Office. The USPTO has given the KYRIX trademark a serial number of 97411368. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Wednesday, September 11, 2024. This trademark is owned by Bridge Biotherapeutics Inc.. The KYRIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biopharmaceutical preparations for the treatment and prevention of cancer, fibrosis, and inflammatory diseases for therapeutical applications excluding prescription pharmaceutical and medicinal preparations for the treatment and prevention of kidney diseases and disorders, administered in any way other than topically, and excluding anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology
kyrix

General Information


Serial Number97411368
Word MarkKYRIX
Filing DateSunday, May 15, 2022
Status645 - FINAL REFUSAL - MAILED
Status DateWednesday, September 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and biopharmaceutical preparations for the treatment and prevention of cancer, fibrosis, and inflammatory diseases for therapeutical applications excluding prescription pharmaceutical and medicinal preparations for the treatment and prevention of kidney diseases and disorders, administered in any way other than topically, and excluding anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBridge Biotherapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNewton,, MA 02458

Trademark Events


Event DateEvent Description
Wednesday, May 18, 2022NEW APPLICATION ENTERED
Wednesday, May 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 20, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, May 27, 2022ASSIGNED TO LIE
Wednesday, June 1, 2022PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Friday, March 3, 2023ASSIGNED TO EXAMINER
Wednesday, April 19, 2023NON-FINAL ACTION WRITTEN
Wednesday, April 19, 2023NON-FINAL ACTION E-MAILED
Wednesday, April 19, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 18, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 18, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 18, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 11, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, September 11, 2024FINAL REFUSAL WRITTEN
Wednesday, September 11, 2024FINAL REFUSAL E-MAILED